Incannex Receives HREC Approval for Phase 2 Clinical Trial Assessing IHL-675A for use in Treatment of Pain and Function in Rheumatoid Arthritis
July 13, 2023 08:00 ET
|
Incannex Healthcare
Highlights: Incannex has received approval from HREC for the lead site, Emeritus Research, Camberwell, VIC for the Phase 2, Blinded, Placebo Controlled Clinical Trial to Determine the Effect on Pain...
Dr. Fatima Cody Stanford, Associate Professor of Medicine and Pediatrics at Harvard Medical School, Joins Clearmind Medicine's Scientific Advisory Board
July 11, 2023 08:30 ET
|
Clearmind Medicine Inc.
Tel Aviv, Israel/Vancouver, Canada, July 11, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "Company"), a biotech company focused on discovery...
Incannex Announces Intention to Redomicile to United States, List all Shares on Nasdaq
July 10, 2023 07:30 ET
|
Incannex Healthcare
Highlights: Incannex to redomicile to the United States via a Scheme of Arrangement pursuant to Australian lawA newly formed Delaware corporation (Incannex Healthcare Inc.) will become the ultimate...
Psychedelic Therapeutics Market Grow at a CAGR 14.92 % from 2023 to 2031 | Exclusive InsightAce Report
June 27, 2023 10:20 ET
|
InsightAce Analytic Pvt. LTd.
Jersey City, NJ, June 27, 2023 (GLOBE NEWSWIRE) -- InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the “Global Psychedelic Therapeutics Market Size, Share &...
Incannex Announces Participation at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference June 26, 2023
June 23, 2023 08:00 ET
|
Incannex Healthcare
MELBOURNE, Australia, June 23, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a pharmaceutical company developing medicinal cannabinoid...
Incannex Appoints Principal Investigators for IHL-42X Phase 2/3 Clinical Trial
June 16, 2023 08:00 ET
|
Incannex Healthcare
MELBOURNE, Australia, June 16, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a clinical-stage pharmaceutical company developing unique...
Beckley Waves Establishes Ethics Council to Guide Industry Standards and Best Practices During Inaugural Summit of The World’s Leaders in Psychedelics
June 01, 2023 09:00 ET
|
Beckley Waves
The New Ethics Council will Work Alongside Beckley Waves to set the Standard for Sustainable and Ethical Operations in the Burgeoning Psychedelics Sector Experts Involved in the Council Include Paul...
Silo Pharma Commences Study of Novel Joint Homing Peptide SPU-21
May 30, 2023 09:00 ET
|
Silo Pharma, Inc.
Phase 2 of study will further investigate the peptides’ method, optimization, and binding affinity in human tissue ENGLEWOOD CLIFFS, NJ, May 30, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq:...
Incannex Company Presentation – Presentation of Psychennex, Psychedelic Therapies Subsidiary Company
May 16, 2023 07:50 ET
|
Incannex Healthcare
MELBOURNE, Australia, May 16, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Ltd (Nasdaq: IXHL) (ASX: IHL) (‘Incannex’ or ‘the Company’) is pleased to announce a company presentation which details...
Silo Pharma to Present at Psychedelic Drug Development Conference
April 24, 2023 08:15 ET
|
Silo Pharma, Inc.
ENGLEWOOD CLIFFS, NJ, April 24, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional...